Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 171

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions

Bradford, Diana, Larkins, Erin, Mushti, Sirisha L., Rodriguez, Lisa, Skinner, Amy M., Helms, Whitney S., Price, Lauren S.L., Zirkelbach, Jeanne Fourie, Li, Yangbing, Liu, Jiang, Charlab, Rosane, Turcu, Francisca Reyes, Liang, Dun, Ghosh, Soma, Roscoe, Donna, Philip, Reena, Zack-Taylor, Autumn, Tang, Shenghui, Kluetz, Paul G., Beaver, Julia A., Pazdur, Richard, Theoret, Marc R., Singh, Harpreet · 2021 · Clinical Cancer Research

Abstract

On May 8, 2020, the FDA granted accelerated approval to selpercatinib for (i) adult patients with metastatic RET fusion–positive non–small cell lung cancer (NSCLC), (ii) adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy, and (iii) adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion–positive thyroid cancer who require systemic therapy and who are radioactive iodine refractory (if radioactive iodine is appropriate). Approval was granted on the basis of the clinically important effects on the overall response rate (ORR) with prolonged duration of responses observed in a multicenter, open-label, multicohort clinical trial (LIBRETTO-001, NCT03157128) in patients whose tumors had RET alterations. ORRs within the approved patient populations ranged from 64% [95% confidence interval (CI), 54–73] in prior platinum-treated RET fusion–positive NSCLC to 100% (95% CI, 63–100) in systemic therapy–naïve RET fusion–positive thyroid cancer, with the majority of responders across indications demonstrating responses of at least 6 months. The product label includes warnings and precautions for hepatotoxicity, hypertension, QT interval prolongation, hemorrhagic events, hypersensitivity, risk of impaired wound healing, and embryo-fetal toxicity. This is the first approval of a drug specifically for patients with RET alterations globally.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-3558

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 171

Metadata

Authors
Bradford, D., Larkins, E., Mushti, S. L., Rodriguez, L., Skinner, A. M., Helms, W. S., Price, L. S. L., Zirkelbach, J. F., Li, Y., Liu, J., Charlab, R., Turcu, F. R., Liang, D., Ghosh, S., Roscoe, D., Philip, R., Zack-Taylor, A., Tang, S., Kluetz, P. G., Beaver, J. A., Pazdur, R., Theoret, M. R., & Singh, H.
Venue
Clinical Cancer Research
Published
2020-11-25
Volume
27
Issue
8
Pages
2130-2135
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3106635148
Cited by
171
References
1
FWCI
11.94
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-3558
The paper
Bradford, D., Larkins, E., Mushti, S. L., Rodriguez, L., Skinner, A. M., Helms, W. S., Price, L. S. L., Zirkelbach, J. F., Li, Y., Liu, J., Charlab, R., Turcu, F. R., Liang, D., Ghosh, S., Roscoe, D., Philip, R., Zack-Taylor, A., Tang, S., Kluetz, P. G., . . . Singh, H. (2021). FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-3558

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.